IMV Inc: Surges as potential COVID-19 vaccine nears clinical trials

Imv

14/07/2020 16:18

(Updates)
    ** U.S.-listed shares of Canadian drug developer  IMV.O 
surge 80.7% to $5.41 - set for best day ever 
    ** Co says Health Canada has agreed on protocol of an
early-stage trial of co's experimental COVID-19 vaccine; IMV is
gearing up to submit clinical trial application  urn:newsml:reuters.com:*:nBw1mVwq8a
    ** IMV expects to begin the trial later in the summer, with
results by fall 
    ** Says study will test two doses of co's vaccine,
DPX-COVID-19
    ** Brokerage BTIG says IMV's peptide vaccine, which focuses
on generating virus-neutralizing antibodies, will take center
stage if other leading, spike-protein focused candidates fail
due to safety issues
    ** Separately, privately held Canadian company Medicago has
started testing its plant-based COVID-19 vaccine in an
early-stage clinical trial  urn:newsml:reuters.com:*:nL3N2EK3DD
    ** Including session's gains, IMV up >80% YTD 

 (Reporting by Manas Mishra in Bengaluru)
 ((Manas.Mishra@thomsonreuters.com;
www.twitter.com/Manasmishra24; within U.S. +1 646 223 8780,
outside U.S. +91 806749 2709;))